First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer Reporter: Aviva Lev-Ari, PhD, RN Intellia to kick-start first single-course ‘curative’ CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer by Ben Adams | Oct 19, 2020 10:39am It’s been a good year for Intellia: One of its founders, Jennifer Doudna, […]
Search Results for 'CRISPR'
From AAAS Science News on COVID19: New CRISPR based diagnostic may shorten testing time to 5 minutes
Posted in Biomarkers: Inflammation, Cancer Researchers Fighting COVID-19, Coronavirus Gene Expression, COVID-19, COVID-19, COVID-19: Pandemic Surgery Guidance, CRISPR/Cas9 & Gene Editing, Population genetics, Population Health Management, Population Health Management, Genetics & Pharmaceutical, SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus, SARS-CoV-2, Seasonality & Environmental Factors in Resurgence, Treatment Protocols for COVID-19, Virus Infective Acute Respiratory Syndrome: SARS-CoV, tagged #COVID-19, AAAS, coronavirus, CRISPR, CRISPR –Cas9 system for genetic engineering, CRISPR/Cas and crispr, Jennifer Doudna, Molecular Diagnostics, rapid testing, SARS-CoV-2, SARS-CoV-2 Entry Factors, Single-molecule detection, Virus Infective Acute Respiratory Syndrome: SARS-CoV | Tagged COVID-19 on October 11, 2020| Leave a Comment »
From AAAS Science News on COVID19: New CRISPR based diagnostic may shorten testing time to 5 minutes Reporter: Stephen J. Williams, Ph.D. A new CRISPR-based diagnostic could shorten wait times for coronavirus tests. New test detects coronavirus in just 5 minutes By Robert F. ServiceOct. […]
Prime Editing as a New CRISPR Tool to Enhance Precision and Versatility
Posted in CAR-T, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, Disease Biology, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genome Biology, tagged Broad Institute, CRISPR, CRISPR –Cas9 system for genetic engineering, CRISPR-based gene editing, Editas, gene editing technology platform, genetic engineering, Nature, off target effects, Tay-Sachs on August 29, 2020| 1 Comment »
Prime Editing as a New CRISPR Tool to Enhance Precision and Versatility Reporter: Stephen J. Williams, PhD CRISPR has become a powerful molecular for the editing of genomes tool in research, drug discovery, and the clinic (see posts and ebook on this site below) Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene […]
CRISPR-Cas9 and the Power of Butterfly Gene Editing
Posted in Behavioral Genetics, CRISPR alternative for editing genes without cutting, CRISPR/Cas9 & Gene Editing, Genome Biology, Microbiologial genetics, Transcriptomics on August 23, 2020| Leave a Comment »
CRISPR-Cas9 and the Power of Butterfly Gene Editing Reporter: Madison Davis Genome editing is a relatively new branch of genetic engineering that utilizes modern technologies in altering, inserting, or deleting selective DNA sequences within cells. CRISPR-Cas9, otherwise known as “Clustered Regularly Interspaced Short Palindromic Repeat”, is a groundbreaking genome editing technique for scientists, as it […]
CRISPR companies calling for article retraction from Nature Methods – If the same or similar sequence of letters appears elsewhere in the genome, that can result in an unintentional or off-target edit – Concerns of Harm caused by Gene Editing using CRISPR-Cas9
Posted in CRISPR/Cas9 & Gene Editing on November 12, 2019| 2 Comments »
CRISPR companies calling for article retraction from Nature Methods – If the same or similar sequence of letters appears elsewhere in the genome, that can result in an unintentional or off-target edit – Concerns of Harm caused by Gene Editing using CRISPR-Cas9 Reporter: Aviva Lev-Ari, PhD, RN Storm around the call for “Nature Methods […]
CRISPR Cuts Turn Gels into Biological Watchdogs
Posted in CRISPR/Cas9 & Gene Editing, tagged Cas12a, CRISPR, CRISPR-based gene editing, human genome, hydrogel on August 30, 2019| Leave a Comment »
Update 6/11/2020 CRISPR-IL used to develop next-gen genome editing products Haifa-based Pluristem Therapeutics is a regenerative medicine company that plans to develop next-generation multi-species genome editing products for human, plant and animal DNA that could improve work done in the pharma, agriculture and aquaculture industries. The CRISPR-IL consortium includes Sheba Medical Center and Schneider Children’s Medical […]
On July 19, 2019, Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office (USPTO) to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley (UC Berkeley).
Posted in Uncategorized on July 23, 2019| Leave a Comment »
Merck KGaA-owned Sigma-Aldrich has petitioned the US Patent and Trademark Office (USPTO) to open an interference proceeding between its own pending CRISPR-Cas9 patents and patents awarded to the University of California, Berkeley (UC Berkeley). On Friday, July 19, Sigma-Aldrich submitted the request, available on blog PatentDocs, asking for a parallel interference to the one declared by the […]
At Technical University of Munich (TUM) Successful Genetical modification of a patient’s own immune cells, T cell receptors, using CRISPR-Cas9 gene editing tool. The engineered T cells are very similar to the physiological immune cells.
Posted in CRISPR/Cas9 & Gene Editing on July 17, 2019| Leave a Comment »
At Technical University of Munich (TUM) Successful Genetical modification of a patient’s own immune cells, T cell receptors, using CRISPR-Cas9 gene editing tool. The engineered T cells are very similar to the physiological immune cells. Reporter: Aviva Lev-Ari, PhD, RN Targeted exchange using the CRISPR-Cas9 gene scissors The problem with conventional methods is that the […]
FIVE Forthcoming Books on CRISPR in 2019-2020: Flooded market or CRISPR-fatigued readers – Not to Worry !!!!!
Posted in CRISPR/Cas9 & Gene Editing on July 4, 2019| Leave a Comment »
FIVE Forthcoming Books on CRISPR in 2019-2020: Flooded market or CRISPR-fatigued readers – Not to Worry !!!!! Author: Aviva Lev-Ari, PhD, RN From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> Date: Thursday, July 4, 2019 at 8:39 PM To: <damian.garde@statnews.com> Cc: Marcus W Feldman <mfeldman@stanford.edu>, “Stephen Williams, PhD” <sjwilliamspa@comcast.net>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, Gail Thornton <gailsthornton@yahoo.com> Subject: Regarding your […]